Detalhe da pesquisa
1.
Occurrence and predictors of acute stent recoil-A comparison between the xience prime cobalt chromium stent and the promus premier platinum chromium stent.
Catheter Cardiovasc Interv
; 91(3): E21-E28, 2018 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28500738
2.
VEGF165A microsphere therapy for myocardial infarction suppresses acute cytokine release and increases microvascular density but does not improve cardiac function.
Am J Physiol Heart Circ Physiol
; 309(3): H396-406, 2015 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26024685
3.
APPOSITION V: STENTYS coronary stent system clinical trial in subjects with ST-segment elevation myocardial infarction--rationale and design.
Am Heart J
; 168(5): 652-60, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25440792
4.
Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial.
Lancet
; 380(9852): 1482-90, 2012 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-22951305
5.
Vascular compliance changes of the coronary vessel wall after bioresorbable vascular scaffold implantation in the treated and adjacent segments.
Circ J
; 76(7): 1616-23, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22531596
6.
Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial.
Eur Heart J
; 32(19): 2454-63, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21659439
7.
A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds.
Eur Heart J
; 32(3): 294-304, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21123276
8.
Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial.
EuroIntervention
; 17(18): 1467-1476, 2022 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35285803
9.
Long-term tissue coverage of a biodegradable polylactide polymer-coated biolimus-eluting stent: comparative sequential assessment with optical coherence tomography until complete resorption of the polymer.
Am Heart J
; 162(5): 922-31, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22093210
10.
An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study.
Eur Heart J
; 31(2): 165-76, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19889649
11.
Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial.
Lancet
; 372(9644): 1163-73, 2008 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-18765162
12.
Five-year optical coherence tomography follow-up of an everolimus-eluting bioresorbable vascular scaffold: changing the paradigm of coronary stenting?
Circulation
; 126(7): e89-91, 2012 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-22891170
13.
Conformability in everolimus-eluting bioresorbable scaffolds compared with metal platform coronary stents in long lesions.
Int J Cardiovasc Imaging
; 33(12): 1863-1871, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28685314
14.
The Promus Premier everolimus-eluting platinum chromium stent with durable polymer evaluated in a real world all-comer population in Rotterdam cardiology hospital (the P-SEARCH registry).
Int J Cardiol
; 240: 103-107, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28385356
15.
One-Year Clinical Outcomes of Patients Presenting With ST-Segment Elevation Myocardial Infarction Caused by Bifurcation Culprit Lesions Treated With the Stentys Self-Apposing Coronary Stent: Results From the APPOSITION III Study.
J Invasive Cardiol
; 29(8): 253-258, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28756418
16.
Everolimus-eluting bioresorbable vascular scaffolds implanted in coronary bifurcation lesions: Impact of polymeric wide struts on side-branch impairment.
Int J Cardiol
; 221: 656-64, 2016 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27423087
17.
A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up.
J Am Coll Cardiol
; 67(7): 766-76, 2016 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-26892411
18.
Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS all-comers trial.
Cardiol J
; 23(6): 626-636, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27665852
19.
Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.
JACC Cardiovasc Interv
; 9(16): 1652-63, 2016 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27476094
20.
Is it safe to implant bioresorbable scaffolds in ostial side-branch lesions? Impact of 'neo-carina' formation on main-branch flow pattern. Longitudinal clinical observations.
Atherosclerosis
; 238(1): 22-5, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25437885